Evidence map›Paper›PMID 38093494›Full record

ArticleESC heart failure2024

The 'peptide for life' initiative in the emergency department study.

Antoni Bayes-Genis, Gordana Krljanac, Marija Zdravković, Milika Ašanin, Anastazija Stojšić-Milosavljević, Slavica Radovanović, Tamara Preradović Kovačević, Aleksandar Selaković, Ivan Milinković, Marija Polovina and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 12 countries.

Antoni Bayes-GenisHeart Institute, Hospital Universitari Germans Trias i Pujol, CIBERCV, Barcelona, Spain.
Gordana KrljanacCardiology Clinic, University Medical Center, Medical Faculty University of Belgrade, Belgrade, Serbia.
Marija ZdravkovićMedical Faculty University of Belgrade, University Clinical Hospital Center Bezanijska kosa, Belgrade, Serbia.
Milika AšaninCardiology Clinic, University Medical Center, Medical Faculty University of Belgrade, Belgrade, Serbia.
Anastazija Stojšić-MilosavljevićCardiology Clinic, Institute for Cardiovascular Diseases of Vojvodina, Medical Faculty University of Novi Sad, Novi Sad, Serbia.
Slavica RadovanovićDepartment of Cardiology, University Clinical Hospital Center 'Dr Dragisa Misovic-Dedinje', Belgrade, Serbia.
Tamara Preradović KovačevićClinic for Cardiovascular Diseases, University Clinical Centre of the Republic of Srpska, Medical Faculty, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
Aleksandar SelakovićClinic for Internal Medicine, General Hospital Užice, Užice, Serbia.
Ivan MilinkovićCardiology Clinic, University Medical Center, Medical Faculty University of Belgrade, Belgrade, Serbia.
Marija PolovinaCardiology Clinic, University Medical Center, Medical Faculty University of Belgrade, Belgrade, Serbia.
Duška GlavašDepartment of Cardiovascular Medicine, Clinical Hospital Center Split, University of Split Faculty of Medicine, Split, Croatia.
Elizabeta SrbinovskaUniversity Clinic of Cardiology, Skopje, Macedonia.
Nebojša BulatovićCardiology Clinic, Clinical Center Podgorica, School of Medicine University of Podgorica, Podgorica, Montenegro.
Davor MiličićUniversity of Zagreb School of Medicine, Department of Cardiovascular Diseases, University Hospital Center Zagreb, Zagreb, Croatia.
Maja ČikešUniversity of Zagreb School of Medicine, Department of Cardiovascular Diseases, University Hospital Center Zagreb, Zagreb, Croatia.
Zdravko BabićClinic for Cardiovascular diseases, University Hospital Center Sestre milosrdnice, Zagreb, Croatia.
Jozica ŠikićDepartment for Cardiovascular Diseases, School of Medicine, Clinical Hospital Center Sveti Duh, University of Zagreb, Zagreb, Croatia.
Zumreta KušljugićMedical School and University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina.
Larisa Dizdarević HudićMedical School and University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina.
Henrike ArfstenDepartment of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
Laura M G MeemsDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Marco MetraDepartment of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, ASST Spedali Civili, University of Brescia, Brescia, Italy.
Giuseppe RosanoIRCCS San Raffaele Pisana, Rome, Italy.
Petar M SeferovićMedical Faculty University of Belgrade, Serbian Academy of Sciences and Arts, University Medical Center, Belgrade, Serbia.
Young Investigators of the Peptide for Life Initiative
University of Belgrade · RSGrade Medical (Czechia) · CZUniversity of Zagreb · HRHospital Universitari Germans Trias i Pujol · ESInstitute for Cardiovascular Diseases of Vojvodina · RSIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleKlinički Centar Crne Gore · MEMedical University of Vienna · ATRazi Hospital · IRSisters of Charity Hospital · HRUniversity Clinical Center Tuzla · BAUniversity Clinic of Traumatology · ATUniversity Hospital Center Dr Dragiša Mišović · RSUniversity Hospital Centre Zagreb · HRUniversity Hospital Medical Center Bezanijska kosa · RSUniversity of Banja Luka · BAUniversity of Brescia · ITUniversity of Groningen · NLUniversity of Split · HRUniversity of Tuzla · BA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsNatriuretic peptide (NP) uptake varies in Emergency Departments (EDs) across Europe. The 'Peptide for Life' (P4L) initiative, led by Heart Failure Association, aims to enhance NP utilization for early diagnosis of heart failure (HF). We tested the hypothesis that implementing an educational campaign in Western Balkan countries would significantly increase NP adoption rates in the ED. METHODS AND

resultsThis registry examined NP adoption before and after implementing the P4L-ED study across 10 centres in five countries: Bosnia and Herzegovina, Croatia, Montenegro, North Macedonia, and Serbia. A train-the-trainer programme was implemented to enhance awareness of NP testing in the ED, and centres without access received point-of-care instruments. Differences in NP testing between the pre-P4L-ED and post-P4L-ED phases were evaluated. A total of 2519 patients were enrolled in the study: 1224 (48.6%) in the pre-P4L-ED phase and 1295 (51.4%) in the post-P4L-ED phase. NP testing was performed in the ED on 684 patients (55.9%) during the pre-P4L-ED phase and on 1039 patients (80.3%) during the post-P4L-ED phase, indicating a significant absolute difference of 24.4% (95% CI: 20.8% to 27.9%, P < 0.001). The use of both NPs and echocardiography significantly increased from 37.7% in the pre-P4L-ED phase to 61.3% in the post-P4L-ED phase. There was an increased prescription of diuretics and SGLT2 inhibitors during the post-P4L-ED phase.

conclusionsBy increasing awareness and providing resources, the utilization of NPs increased in the ED, leading to improved diagnostic accuracy and enhanced patient care.

Indexed as

Emergency Service, HospitalHeart FailureEchocardiographyEuropeHumansNatriuretic PeptidesNatriuretic PeptidesAccessAdoptionAwarenessEmergency departmentNatriuretic peptidesPeptide for life

Identifiers

PMID38093494
PMCPMC10966210
OpenAlexW4389764228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.